This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

10.1 Mergers and Acquisitions 74

10.1.1 M&A by Year 74

10.1.2 M&A by Value 75

10.1.3 M&A by Type 75

10.1.4 M&A Deals 76

10.2 Licensing Agreements 78

10.3 Co-developments 80

11 Biosimilars in Emerging Economies – Appendix 82

11.1 Market Definitions 82

11.2 Abbreviations 82

11.3 Bibliography 84

11.4 Research Methodology 86

11.4.1 Market Overview 87

11.4.2 Market Characterization 87

11.4.3 India 87

11.4.4 China 87

11.4.5 Other Emerging Economies 87

11.4.6 Pipeline Analysis 88

11.4.7 Industry Dynamics 88

11.4.8 Deals Analysis 88

11.5 Contact Us 88

11.6 Disclaimer 88

 

 

 

List of Tables

 

Table 1: Biosimilars in Emerging Economies, Key Patent Expiries of Leading Biologics From 2011–2018 23

Table 2: Biosimilars in Emerging Economies, Revenue ($bn), 2002–2011 24

Table 3: Biosimilars in Emerging Economies, Revenue Forecasts ($bn), 2011–2018 24

Table 4: Biosimilars in Emerging Economies, Marketed Biosimilar Products, India, 2012 25

Table 5: Biosimilars in Emerging Economies, Marketed Biosimilar Products, China, 2012 26

Table 6: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Other Emerging Economies, 2012 27

Table 7: Biosimilars in Emerging Economies, India, Revenue ($bn), 2002–2011 28

Table 8: Biosimilars in Emerging Economies, India, Revenue Forecasts ($bn), 2011–2018 28

Table 9: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Dr. Reddy's, 2012 31

Table 10: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Biocon, 2012 33

Table 11: Biosimilars in Emerging Economies, Pipeline Molecules, Biocon, 2012 33

Table 12: Biosimilars in Emerging Economies, Marketed Biosimilar Products, IBPL, 2012 34

Table 13: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Reliance Life Sciences, 2012 36

Table 14: Biosimilars in Emerging Economies, Pipeline Molecules, Reliance Life Sciences, 2012 37

Table 15: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Wockhardt, 2012 38

5 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs